Please ensure Javascript is enabled for purposes of website accessibility

Big Day on Deck for Flexion Therapeutics

By Todd Campbell - Updated Oct 10, 2017 at 2:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA decision on the company's osteoarthritis pain of the knee drug is expected on Oct. 6.

Flexion Therapeutics (FLXN) is about to find out if its research efforts will pay off. The U.S. Food and Drug Administration is expected to issue a go/no-go decision on its treatment for osteoarthritis pain of the knee -- Zilretta -- on Oct. 6, and because Zilretta is the company's closest drug to commercialization, the regulators' decision could create a wild swing higher or lower in the company's stock price.

Is this company about to become the standard of care or will the FDA give Zilretta a red light?

A big market opportunity

Flexion Therapeutics thinks quarterly Zilretta injections can deliver greater pain relief for osteoarthritis of the knee patients than corticosteroids. Results from one phase 3 trial suggest that's true.

A man in shorts rubbing his knee.

IMAGE SOURCE: GETTY IMAGES.

Currently, about 5 million Americans receive quarterly corticosteroid shots, but these shots offer inadequate relief for many. Pain reduction can begin to wane only a few weeks after injection, and often the benefit of the treatment has disappeared altogether prior to the next scheduled dose. As a result, patients may increase their use of rescue pain relievers, including opioids. 

Zilretta is an extended-release formulation of a long-used, short-acting corticosteroid called triamcinolone acetonide. Flexion Therapeutics uses a proprietary microsphere technology to combine the corticosteroid with a poly lactic-co-glycolic acid. The formulation allows for a slow release of triamcinolone acetonide that appears to provide more sustainable pain relief.

In trials, Zilretta reduced pain in patients with osteoarthritis of the knee by a median 50% at the 12-week mark. If the drug is approved, its efficacy and duration of effect may allow it to replace the use of corticosteroid shots in millions of patients, especially since it could reduce the need for rescue drugs, including habit-forming ones.

Management suggests a price of $500 per injection, or $2,000 annually, would be supported by insurers. If so, then a big patient population could turn Zilretta into a nine-figure drug. For perspective on the market opportunity, Sanofi's Synvisc-One, a hyaluronan injection for knee pain, produces about $400 million in annual revenue.

Risks remain

There are about 14 million people who suffer from osteoarthritis of the knee, and roughly 40% of osteoarthritis patients are prescribed opiate pain relievers. Given the big need for treatment alternatives that could reduce opioid prescriptions, Zilretta's solid efficacy and potential to decrease the need for rescue drugs may position it nicely for a regulatory OK. In the past, the FDA has been vocal in encouraging the development of new pain treatments, and that objective may tilt its decision on Zilretta in favor of Flexion Therapeutics.

That said, there's no guarantee that regulators will green-light Zilretta. They could ask for more data to confirm its benefit, question manufacturing, or reject it outright. A rejection would undeniably be bad news for Flexion Therapeutics' shareholders because Zilretta is the only drug in its pipeline.

Unquestionably, this makes buying shares ahead of tomorrow's FDA decision a risky proposition. An OK could catapult shares higher, particularly since 27% of Flexion Therapeutics' share float is held short. Alternatively, a rejection would probably cause shares to crash. Overall, Flexion Therapeutics has a solid shot at winning a Zilretta approval, but buying its shares ahead of this decision may be too risky for most investors.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Flexion Therapeutics, Inc. Stock Quote
Flexion Therapeutics, Inc.
FLXN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.